|
Genotypes
|
Case No.
|
Deaths No. (%)*
|
MST (95% CI, month)
|
Crude HR (95% CI)
|
P
†
|
Adjusted HR (95% CI)
|
P
‡
|
|---|
|
VEGF-460T > C (rs833061)
| | | | | |
|---|
|
TT
|
33
|
28 (84.9)
|
16.0 (11.0-25.0)
|
1.00
| |
1.00
| |
|
CT
|
67
|
47 (70.2)
|
21.0 (17.0-32.0)
|
0.60 (0.37-0.95)
|
0.031
|
0.56 (0.34-0.90)
|
0.018
|
|
CC
|
24
|
17 (70.8)
|
27.0 (10.0-36.0)
|
0.75 (0.41-1.37)
|
0.347
|
0.67 (0.36-1.26)
|
0.212
|
|
CT+CC
|
91
|
64 (70.3)
|
21.0 (17.0-31.0)
|
0.63 (0.40-0.99)
|
0.043
|
0.58 (0.37-0.92)
|
0.022
|
|
VEGF
-634G > C (rs2010963)
| | | | | |
|
GG
|
57
|
40 (70.2)
|
23.0 (16.0-36.0)
|
1.00
| |
1.00
| |
|
CG
|
41
|
34 (82.9)
|
17.0 (13.0-25.0)
|
1.20 (0.76-1.90)
|
0.440
|
1.17 (0.74-1.88)
|
0.502
|
|
CC
|
26
|
18 (69.2)
|
12.0 (9.0-29.0)
|
1.25 (0.71-2.18)
|
0.436
|
1.28 (0.72-2.28)
|
0.399
|
|
CG+CC
|
67
|
52 (76.1)
|
17.0 (12.0-24.0)
|
1.22 (0.80-1.84)
|
0.356
|
1.21 (0.79-1.84)
|
0.379
|
|
VEGF
+936C > T (rs3025039)
| | | | | |
|
CC
|
92
|
68 (73.9)
|
21.0 (16.0-29.0)
|
1.00
| |
1.00
| |
|
CT
|
30
|
22 (73.3)
|
17.0 (11.0-29.0)
|
1.08 (0.67-1.75)
|
0.742
|
1.00 (0.60-1.66)
|
0.992
|
|
TT
|
2
|
2 (100)
|
14.5 (9.0-20.0)
|
2.14 (0.52-8.80)
|
0.291
|
1.95 (0.46-8.29)
|
0.367
|
|
CT+TT
|
32
|
24 (75.0)
|
17.0 (11.0-28.0)
|
1.13 (0.71-1.80)
|
0.606
|
1.05 (0.65-1.71)
|
0.839
|
- Abbreviation: MST, median survival time.
- * Percentage of deaths in each stratum
- † P values were calculated using the log-rank test in the univariate analysis.
- ‡ P values were obtained from the Cox hazards model with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and radiotherapy dose.
